Francine Bridges
Adult Health · Tallahassee, FLNPI 1538487079
Payments from drug & device makers
Across 210 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$756
- Jazz Pharmaceuticals Inc.$337
- AstraZeneca$336
- Sanofi$336
- Regeneron Healthcare Solutions, Inc.$293
- Actelion Pharmaceuticals US, Inc.$271
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,505100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $756 |
| Jazz Pharmaceuticals Inc. | 15 | $337 |
| AstraZeneca | 11 | $336 |
| Sanofi | 15 | $336 |
| Regeneron Healthcare Solutions, Inc. | 15 | $293 |
| Actelion Pharmaceuticals US, Inc. | 9 | $271 |
| Insmed, Inc. | 13 | $270 |
| GSK | 16 | $256 |
| Mylan Specialty L.p. | 12 | $203 |
| Mallinckrodt Hospital Products Inc. | 10 | $181 |
| Harmony Biosciences LLC | 8 | $164 |
| Electromed, Inc. | 12 | $133 |
| Pulmonx Corporation | 1 | $129 |
| Verona Pharma, Inc. | 5 | $117 |
| ANI Pharmaceuticals, Inc. | 4 | $109 |
| Lilly USA, LLC | 2 | $106 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Grifols USA, LLC | 2 | $59 |
| United Therapeutics Corporation | 4 | $52 |
| Baxter Healthcare | 2 | $49 |
| Merck | 2 | $46 |
| Inspire Medical Systems, Inc. | 2 | $43 |
| Amgen | 2 | $40 |
| Viatris Specialty LLC | 2 | $36 |
| Philips North America LLC | 1 | $24 |
| Inogen, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,521 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 473 | $383,057 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 163 | $86,510 |
| Breo ElliptaFluticasone/Vilanterol | 190 | $85,819 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $77,433 |
| Spiriva HandihalerTiotropium Bromide | 39 | $30,439 |
| BreynaBudesonide/Formoterol Fumarate | 50 | $16,372 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $16,043 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $14,229 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $13,318 |
| Arnuity ElliptaFluticasone Furoate | 32 | $10,495 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 273 | $8,483 |
| Ventolin HfaAlbuterol Sulfate | 116 | $7,058 |
| Spiriva RespimatTiotropium Bromide | 12 | $5,995 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $5,797 |
| Wixela InhubFluticasone Propion/Salmeterol | 48 | $4,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $256 | $571,679869 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $336 | $96,096163 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $756 | $22,03837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Tallahassee
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.